Affirms U.S. LINZESS Net Sales view of $800M – $850M. High single digit prescription demand growth, more than offset by expected price erosion due to Medicare Part D redesign.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD:
- Ironwood Pharma: Hold Rating Maintained Amid Revenue Uncertainty and Long-term Concerns
- IRWD Earnings this Week: How Will it Perform?
- Ironwood backs FY25 revenue view $260M-$290M, consensus $287.07M
- Ironwood downgraded to Hold from Buy at Craig-Hallum
- Ironwood Pharma: Hold Rating Amid Uncertainty Over Apraglutide’s Phase 3 Trial and Strategic Options